NOR-101's IL-18 Hypothesis Is the Only Differentiator — and It Has Zero Clinical Validation

North Immunology Goes Public via Reverse Merger with Aethlon

North Immunology, a biotech startup developing NOR-101 for atopic dermatitis, is set to go public in the first quarter of 2027 through a reverse merger with Aethlon Medical. The combined entity, operating as North Immunology and trading on Nasdaq under “NRTX,” will be primarily owned by North Immunology investors (95.25%). This move is supported by a $180 million private placement from investors like Bain Capital, Janus Henderson, and Deep Track Capital, which is expected to fund operations into the second half of 2028. NOR-101, a dual-acting antibody targeting IL-13 and IL-18, aims to offer a superior profile compared to existing treatments like Dupixent, with a Phase 1a study planned for early next year.

• North Immunology is going public via a reverse merger with Aethlon Medical, with the transaction expected to close in Q1 2027. Post-merger, North Immunology investors will own 95.25% of the new entity, which will operate under the North Immunology name and trade on Nasdaq as "NRTX." Aethlon shareholders will receive contingent value rights for their legacy Hemopurifier business.
• The company secured a $180 million private placement from prominent investors including Bain Capital, Janus Henderson, and Deep Track Capital. This substantial capital infusion is projected to fund the combined company's operations and advance its pipeline into the second half of 2028, providing a strong financial runway for its early-stage development.
• North Immunology's lead candidate, NOR-101, is a dual-acting antibody designed to treat atopic dermatitis. It targets both IL-13 and IL-18, two distinct inflammatory pathways. This novel approach aims to overcome limitations of current therapies like Dupixent, which primarily targets IL-13, by potentially delivering a "best-in-disease therapeutic profile."
• NOR-101 is in its early stages, with a Phase 1a study anticipated to commence in the first quarter of next year. The drug enters a competitive market for atopic dermatitis, where established players like Sanofi/Regeneron (Dupixent, with $17.8 billion in sales) and AbbVie (Rinvoq), alongside newer biotechs, are also developing improved treatments.

Navigating the Evolving Atopic Dermatitis Treatment Landscape

The atopic dermatitis (AD) treatment landscape has undergone substantial expansion beyond traditional topical corticosteroids, with multiple mechanistically distinct agents now supported by robust clinical trial data. Among topical therapies, the calcineurin inhibitors pimecrolimus and tacrolimus, alongside the PDE4 inhibitor crisaborole, have demonstrated efficacy in lesion clearance and symptom management across 69 identified clinical trials, with all three agents associated with low systemic absorption and no demonstrated increased risk of malignancy or lymphoma. Real-world data further support crisaborole as effective monotherapy for chronic hyperplastic AD lesions across age groups, with effectiveness appearing independent of AD duration. A network meta-analysis evaluating topical 1.5% ruxolitinib cream — a selective JAK1/JAK2 inhibitor — against systemic agents in patients aged ≥ 12 years with moderate AD found no statistically significant differences between active comparators for IGA 0/1, EASI-75, and Itch NRS4, with point estimates numerically favoring ruxolitinib cream for IGA 0/1 and EASI-75, suggesting topical JAK inhibition may provide disease control comparable to systemic therapies in this population.

In the systemic biologic space, dupilumab has accumulated long-term efficacy and safety data across a broad age range. In adolescents, 52-week data from a phase IIa and open-label extension study showed EASI improvements of −85% ± 12% and −84% ± 20% at week 52 for the 2 mg/kg and 4 mg/kg dose cohorts, respectively. In children aged 6 months to 5 years, a phase 3 open-label extension demonstrated that by week 52, 36.2% achieved IGA 0/1, and 96.6%, 79.3%, and 58.6% achieved at least 50%, 75%, or 90% EASI improvement, respectively, with an acceptable safety profile consistent with that observed in adults. Tralokinumab, an IL-13 inhibitor, has also emerged as a meaningful option: pooled data from the ECZTRA 1 and 2 phase III trials showed progressive improvement over 52 weeks, with EASI-75 response rates rising from 37.6% to 61.8% in all patients initiated on tralokinumab. A single-center real-world study of 37 adults further reported that 93% (28/30) achieved IGA 0/1 at 1 year, with no adverse events reported through follow-up.

Oral JAK inhibitors — upadacitinib, abrocitinib, and baricitinib — represent the most recent class to enter the AD armamentarium, offering rapid onset and robust efficacy, particularly in severe or difficult-to-treat disease. A post hoc analysis of the phase 3 JADE COMPARE trial demonstrated that abrocitinib 200 mg achieved significantly greater IGA 0/1, EASI-75, and EASI-90 responses than placebo across all severe and/or difficult-to-treat AD subgroups (nominal p < 0.05), with time to PP-NRS4 response of 4.5–6.0 days versus 8.0–11.0 days for dupilumab. An open-label extension of the Heads Up trial showed that patients switching from dupilumab to upadacitinib 30 mg experienced incremental clinical improvements within 4 weeks, including those who had not achieved adequate responses with dupilumab. However, a population-based cohort study of 938 propensity score-matched patients per group found that oral JAK inhibitor use was associated with significantly higher risks of herpes zoster (HR = 2.51, 95% CI = 1.14–5.52), herpes simplex (HR = 1.64, 95% CI = 1.03–2.61), acne (HR = 2.09, 95% CI = 1.54–2.84), neutropenia (HR = 4.02, 95% CI = 1.91–8.47), and hyperlipidemia (HR = 1.45, 95% CI = 1.09–1.92) compared with dupilumab, underscoring the importance of individualized benefit-risk assessment as the therapeutic options for AD continue to diversify.

Why Current Atopic Dermatitis Treatments Fall Short

Atopic dermatitis is a chronic, relapsing inflammatory condition that demands long-term disease management, yet each available treatment class carries meaningful limitations that complicate sustained use. The therapeutic landscape spans topical agents, conventional immunosuppressants, biologics, and JAK inhibitors — each with distinct safety trade-offs that affect patient selection and dosing strategy.

• Topical corticosteroids (TCS): Prolonged TCS use is associated with adverse cutaneous effects including skin atrophy, rebound flares, and increased percutaneous absorption with potential for adverse systemic effects. Long-term safety data are largely limited to low- to mid-potency products in pediatric populations, leaving a recognized gap in evidence for commonly prescribed mid- to high-potency TCS monotherapy in children.

• Topical calcineurin inhibitors (TCIs — tacrolimus, pimecrolimus): Although long-term studies of up to 4 years have not demonstrated increased risk of infections, lymphomas, or skin cancers, TCIs have carried a Boxed Warning since 2006 based on a theoretical risk of malignancy. This has limited their use for standard-of-care maintenance therapy despite robust safety and efficacy data supporting their long-term use.

• Cyclosporine: While effective for moderate-to-severe AD in adults and children, cyclosporine carries a potential for nephrotoxicity, with significant renal toxicity observed in 0%–9% of pediatric participants across reviewed trials. Trough-level monitoring — standard practice in transplant recipients — is not commonplace in AD management, and its correlation with toxicity or disease activity has not been systematically explored. Data on use in children remain scarce, and use should be limited to cases with precise indication after weighing risks and benefits.

• JAK inhibitors (abrocitinib, baricitinib, upadacitinib): Systemic JAK inhibitors significantly increase the risk of herpes zoster, headache, acne, elevated blood creatinine phosphokinase, and nausea compared with placebo. In a real-world comparative cohort, oral JAKi showed significantly higher risks of skin and subcutaneous tissue infection (HR = 1.35, 95% CI = 1.07–1.69), herpes simplex (HR = 1.64, 95% CI = 1.03–2.61), herpes zoster (HR = 2.51, 95% CI = 1.14–5.52), acne (HR = 2.09, 95% CI = 1.54–2.84), anemia (HR = 1.83, 95% CI = 1.39–2.41), neutropenia (HR = 4.02, 95% CI = 1.91–8.47), thrombocytopenia (HR = 1.76, 95% CI = 1.08–2.89), and hyperlipidemia (HR = 1.45, 95% CI = 1.09–1.92) versus dupilumab. Age further modulates risk: incidence rates for serious AEs, serious infections, herpes zoster, thrombocytopenia, lymphopenia, NMSC, malignancies, major cardiovascular events, and venous thromboembolism were numerically higher in patients aged ≥65 years, underscoring the importance of dose selection in older patients. Across disease indications, JAK inhibitors were associated with a higher incidence of malignancy compared with TNF-α inhibitors (IRR 1.50; 95% CI 1.16–1.94), though not compared with placebo or methotrexate. Most RCT follow-up periods were limited to 16 weeks or less, making long-term cardiovascular and malignancy risk difficult to characterize.

• Biologics (dupilumab, tralokinumab): Dupilumab, while generally well tolerated with low rates of serious adverse events, is associated with conjunctivitis, injection-site reactions, and oral herpes as common adverse reactions; ophthalmic complications occurred at a significantly higher rate versus oral JAKi (HR = 1.49, 95% CI = 1.03–2.17) in real-world data. Tralokinumab's real-world evidence base remains limited — the available cohort comprised only 30 adults — constraining the generalizability of its safety and efficacy conclusions.

• Phenotypic heterogeneity and biomarker gaps: Subgroup analyses of tralokinumab in real-world use revealed superior clinical responses in patients with early-onset AD and atopic comorbidities, and lower total IgE levels at week 16 correlated with better outcomes, suggesting total IgE as a potential biomarker. The absence of validated, routinely used biomarkers to guide treatment selection across the broader AD population remains an unresolved challenge in optimizing therapeutic decisions.

IPO Fuels Novel Atopic Dermatitis Strategy Amidst Competitive Landscape

North Immunology's strategic move to go public via a reverse merger, bolstered by a significant $180 million private placement, underscores a bold bet on its lead candidate, NOR-101, in the challenging atopic dermatitis (AD) landscape. This substantial funding provides the necessary capital to propel NOR-101 into Phase 1a clinical trials, extending operations into the second half of 2028 and signaling strong investor confidence in its novel approach.

NOR-101 is designed as a dual-acting antibody targeting both interleukin-13 (IL-13) and interleukin-18 (IL-18). This mechanism represents a potential differentiation point in a market currently dominated by biologics that primarily block the IL-4/IL-13 pathway (like dupilumab) or specifically neutralize IL-13 (like tralokinumab). Research indicates that IL-13 plays a critical role in type 2 inflammation and skin barrier dysfunction in AD. By additionally targeting IL-18, North Immunology aims to address broader aspects of AD pathogenesis, potentially offering a 'superior profile' to existing treatments and improving outcomes for patients who may not achieve optimal response with current therapies.

However, this ambitious strategy is not without considerable risks. NOR-101 is in its earliest clinical phase, a stage notorious for high attrition rates. The clinical efficacy and safety of combining IL-13 and IL-18 inhibition in humans for AD remain to be established. Furthermore, the AD biologics market is highly competitive, with several approved and emerging therapies. For NOR-101 to succeed, it must demonstrate clear, compelling advantages in efficacy, safety, or patient convenience to carve out a significant market share. The initial Phase 1a data will be crucial in validating the therapeutic hypothesis and shaping its future trajectory.